- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06173531
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Andrew McGinn
- Phone Number: 610-299-6639
- Email: andrew.mcginn@acadia-pharm.com
Study Contact Backup
- Name: Kelly O'Rourke-Kosko
- Phone Number: 609-250-6909
- Email: kkosko@acadia-pharm.com
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T3B 6A8
- Recruiting
- Alberta Diabetes Institute
-
Contact:
- Andrew McGinn
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- Children's of Alabama
-
Contact:
- Andrew McGinn
-
-
California
-
Palo Alto, California, United States, 94304
- Recruiting
- Stanford University School of Medicine
-
Contact:
- Andrew McGinn
-
San Diego, California, United States, 92123
- Recruiting
- Rady Children's Hospital San Diego
-
Contact:
- Andrew McGinn
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
Contact:
- Andrew McGinn
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Recruiting
- University of Iowa
-
Contact:
- Andrew McGinn
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- Recruiting
- Children's Mercy Hospital
-
Contact:
- Andrew McGinn
-
-
New York
-
Brooklyn, New York, United States, 11219
- Recruiting
- Maimonides Medical Center
-
Contact:
- Andrew McGinn
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Recruiting
- Vanderbilt Clinical Research Center
-
Contact:
- Andrew McGinn
-
-
Texas
-
Fort Worth, Texas, United States, 79104
- Recruiting
- Cook Children's Health Care System
-
Contact:
- Andrew McGinn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female and 5 through 30 years of age
- Prader-Willi syndrome with a documented disease-causing mutation
- Increased appetite with decreased satiety accompanied by food seeking (consistent with PWS Nutritional Phase 3)
- HQ-CT total score of ≥13 at Screening and Baseline
- CGI-S score for hyperphagia in PWS of ≥4 at Screening and Baseline
- Lives with a caregiver who understands and is willing and able to adhere to study-related procedures and is willing to participate in all study visits
Exclusion Criteria:
- Genetically diagnosed with Schaaf-Yang syndrome or another genetic, hormonal, or chromosomal cognitive impairment besides PWS
- An active upper respiratory infection at the Screening visit or the Baseline visit
- Any clinically significant cardiovascular disorder, renal, hepatic, gastrointestinal, or respiratory disease, including severe asthma
- History of, or current, cerebrovascular disease, brain trauma, epilepsy, or frequent migraines. A history of febrile seizures is not exclusionary
- Nasal surgery within 1 month of Screening visit or planning to have nasal surgery during the study.
- Unwilling to abstain from nasal saline, other nasal irrigation, and other intranasal medications during the Screening period and through the treatment period of the study
- Clinically significant irritability or agitation, requiring initiation of or increase in the dose of antipsychotic medication, within the 6 months prior to the Screening visit
- Used prostaglandins, prostaglandin analogues, or prostaglandin agonists in the 3 months prior to the Baseline visit. Inhibitors of prostaglandin synthesis, such as nonsteroidal anti-inflammatory drugs, are not exclusionary.
- Started a glucagon-like peptide 1 (GLP-1) agonist within the 6 months prior to the Screening visit. Treatment with GLP-1 agonist is allowed if the subject has been taking it for more than 6 months prior to Screening.
- Used oxytocin, desmopressin (DDAVP), or tesofensine within 6 months prior to the Baseline visit
- Active psychotic symptoms, a history of psychotic symptoms, or a psychotic disorder
- History of suicide attempt or inpatient psychiatric hospitalization
- New food-related interventions, including environment or dietary restrictions, within 1 month of the Screening visit
Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo given TID, identical in appearance respective to carbetocin treatment
|
Experimental: Carbetocin
Carbetocin nasal spray 3.2 mg three times daily (TID)
|
Carbetocin nasal spray 3.2 mg three times daily (TID)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline at Week 12 in caregiver-rated Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score
Time Frame: Baseline to Week 12
|
The HQ-CT is a nine-item questionnaire designed to be completed by caregivers of subjects with PWS. It is a revision of the 11-item HPWSQ-R and has been further validated. The Foundation for Prader-Willi Research has made the HQ-CT available for clinical studies in PWS, and it is the consensus instrument within the PWS research community for measuring observable behaviors that stem from subjects' excessive drive to eat. The HQ-CT should be completed by the same caregiver throughout the study. The HQ-CT will be administered to the caregiver by a rater using standardized prompts. The Food Safe Zone should be administered immediately before administration of the HQ-CT. A higher score on the HQ-CT indicates greater severity of hyperphagia. |
Baseline to Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline at Week 12 in caregiver-rated Clinical Global Impression-Severity (CGI-S) score for PWS
Time Frame: Baseline to Week 12
|
The CGI-S is a rating scale that records a clinician's global impression of the current severity of illness on a seven-point scale, using a range of responses from 1 (normal) to 7 (among the most severely ill subjects).
|
Baseline to Week 12
|
Clinical Global Impression-Change (CGI-C) for PWS score at Week 12
Time Frame: Score at Week 12
|
The CGI-C is a rating scale that records a clinician's global impression of change in severity of illness, using a range of responses from 1 (very much improved) to 7 (very much worse).
|
Score at Week 12
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Disease
- Congenital Abnormalities
- Signs and Symptoms, Digestive
- Overnutrition
- Nutrition Disorders
- Overweight
- Genetic Diseases, Inborn
- Intellectual Disability
- Abnormalities, Multiple
- Chromosome Disorders
- Obesity
- Imprinting Disorders
- Syndrome
- Prader-Willi Syndrome
- Hyperphagia
- Physiological Effects of Drugs
- Reproductive Control Agents
- Oxytocics
- Carbetocin
Other Study ID Numbers
- ACP-101-302
- 2023-506200-24 (Other Identifier: EU CT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperphagia in Prader-Willi Syndrome
-
Ferring PharmaceuticalsCompletedHyperphagia in Prader-Willi SyndromeUnited States
-
University Hospital, ToulouseCompletedPrader Willi SyndromeFrance
-
University of FloridaNational Institutes of Health (NIH)Completed
-
Samsung Medical CenterCompletedObesity | Prader Willi Syndrome
-
Duke UniversityCanadian Institutes of Health Research (CIHR); National Institutes of Health... and other collaboratorsCompleted
-
California State University, FullertonUniversity of FloridaUnknownFamily-based Intervention for Youth With Prader-Willi Syndrome: The Active Play at Home Study (APAH)Childhood Obesity | Prader Willi SyndromeUnited States
-
SanionaCompletedConfirmed Genetic Diagnosis of Prader-Willi SyndromeCzechia, Hungary
-
Weill Medical College of Cornell UniversityNational Institutes of Health (NIH); PWSAUSATerminatedPrader-willi SyndromeUnited States
-
University of FloridaFoundation for Prader-Willi ResearchCompleted
-
Shaare Zedek Medical CenterUnknownPrader Willi Syndrome
Clinical Trials on Carbetocin
-
Ciusss de L'Est de l'Île de MontréalCompletedCesarean Section Complications | Hemodynamic InstabilityCanada
-
University Hospital, Basel, SwitzerlandObstetric Anaesthetists' Association United KingdomCompletedAnesthesia; Reaction | Complications; Cesarean SectionSwitzerland
-
Levo Therapeutics, Inc.CompletedPrader-Willi SyndromeUnited States, Canada, Australia
-
University of British ColumbiaEdwards LifesciencesCompletedPregnancy | Effect of Carbetocin on Cardiovascular SystemCanada
-
Bezmialem Vakif UniversityCompleted
-
Cairo UniversityCompletedAbdominal MyomectomyEgypt
-
Cairo UniversityRecruitingPostpartum HemorrhageEgypt
-
Sohag UniversityAl-Azhar UniversityUnknownPostpartum HemorrhageEgypt
-
National University Hospital, SingaporeNational Healthcare Group, SingaporeCompleted
-
Cairo UniversityCompletedPost Partum Hemorrhage | Obesity, MaternalEgypt